306 related articles for article (PubMed ID: 16459991)
1. Molecular genetics of atypical teratoid/rhabdoid tumor.
Biegel JA
Neurosurg Focus; 2006 Jan; 20(1):E11. PubMed ID: 16459991
[TBL] [Abstract][Full Text] [Related]
2. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors.
Biegel JA; Tan L; Zhang F; Wainwright L; Russo P; Rorke LB
Clin Cancer Res; 2002 Nov; 8(11):3461-7. PubMed ID: 12429635
[TBL] [Abstract][Full Text] [Related]
3. Cyclin D1 is overexpressed in atypical teratoid/rhabdoid tumor with hSNF5/INI1 gene inactivation.
Fujisawa H; Misaki K; Takabatake Y; Hasegawa M; Yamashita J
J Neurooncol; 2005 Jun; 73(2):117-24. PubMed ID: 15981100
[TBL] [Abstract][Full Text] [Related]
4. Germline INI1 mutation in a patient with a central nervous system atypical teratoid tumor and renal rhabdoid tumor.
Biegel JA; Fogelgren B; Wainwright LM; Zhou JY; Bevan H; Rorke LB
Genes Chromosomes Cancer; 2000 May; 28(1):31-7. PubMed ID: 10738300
[TBL] [Abstract][Full Text] [Related]
5. The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors: meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumors.
Biegel JA; Kalpana G; Knudsen ES; Packer RJ; Roberts CW; Thiele CJ; Weissman B; Smith M
Cancer Res; 2002 Jan; 62(1):323-8. PubMed ID: 11782395
[TBL] [Abstract][Full Text] [Related]
6. Rhabdoid tumors: integrating biological insights with clinical success: a report from the SMARCB1 and Rhabdoid Tumor Symposium, Paris, December 12-14, 2013.
Bourdeaut F; Chi SN; Frühwald MC
Cancer Genet; 2014 Sep; 207(9):346-51. PubMed ID: 25468731
[TBL] [Abstract][Full Text] [Related]
7. Aberrations of the hSNF5/INI1 gene are restricted to malignant rhabdoid tumors or atypical teratoid/rhabdoid tumors in pediatric solid tumors.
Uno K; Takita J; Yokomori K; Tanaka Y; Ohta S; Shimada H; Gilles FH; Sugita K; Abe S; Sako M; Hashizume K; Hayashi Y
Genes Chromosomes Cancer; 2002 May; 34(1):33-41. PubMed ID: 11921280
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of the rhabdoid predisposition syndrome in a child: a novel germline hSNF5/INI1 mutation and absence of c-myc amplification.
Fujisawa H; Takabatake Y; Fukusato T; Tachibana O; Tsuchiya Y; Yamashita J
J Neurooncol; 2003 Jul; 63(3):257-62. PubMed ID: 12892231
[TBL] [Abstract][Full Text] [Related]
9. Pathology and diagnosis of SMARCB1-deficient tumors.
Margol AS; Judkins AR
Cancer Genet; 2014 Sep; 207(9):358-64. PubMed ID: 25246033
[TBL] [Abstract][Full Text] [Related]
10. Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations.
Sévenet N; Lellouch-Tubiana A; Schofield D; Hoang-Xuan K; Gessler M; Birnbaum D; Jeanpierre C; Jouvet A; Delattre O
Hum Mol Genet; 1999 Dec; 8(13):2359-68. PubMed ID: 10556283
[TBL] [Abstract][Full Text] [Related]
11. SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.
Kuwahara Y; Wei D; Durand J; Weissman BE
Mol Cancer Res; 2013 Mar; 11(3):251-60. PubMed ID: 23364536
[TBL] [Abstract][Full Text] [Related]
12. Rhabdoid tumor predisposition syndrome.
Sredni ST; Tomita T
Pediatr Dev Pathol; 2015; 18(1):49-58. PubMed ID: 25494491
[TBL] [Abstract][Full Text] [Related]
13. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.
Lee S; Cimica V; Ramachandra N; Zagzag D; Kalpana GV
Cancer Res; 2011 May; 71(9):3225-35. PubMed ID: 21521802
[TBL] [Abstract][Full Text] [Related]
14. hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities.
Bourdeaut F; Fréneaux P; Thuille B; Lellouch-Tubiana A; Nicolas A; Couturier J; Pierron G; Sainte-Rose C; Bergeron C; Bouvier R; Rialland X; Laurence V; Michon J; Sastre-Garau X; Delattre O
J Pathol; 2007 Feb; 211(3):323-30. PubMed ID: 17152049
[TBL] [Abstract][Full Text] [Related]
15. Non-linkage of familial rhabdoid tumors to SMARCB1 implies a second locus for the rhabdoid tumor predisposition syndrome.
Frühwald MC; Hasselblatt M; Wirth S; Köhler G; Schneppenheim R; Subero JI; Siebert R; Kordes U; Jürgens H; Vormoor J
Pediatr Blood Cancer; 2006 Sep; 47(3):273-8. PubMed ID: 16206192
[TBL] [Abstract][Full Text] [Related]
16. hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors.
Rousseau-Merck MF; Versteege I; Legrand I; Couturier J; Mairal A; Delattre O; Aurias A
Cancer Res; 1999 Jul; 59(13):3152-6. PubMed ID: 10397258
[TBL] [Abstract][Full Text] [Related]
17. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer.
Versteege I; Sévenet N; Lange J; Rousseau-Merck MF; Ambros P; Handgretinger R; Aurias A; Delattre O
Nature; 1998 Jul; 394(6689):203-6. PubMed ID: 9671307
[TBL] [Abstract][Full Text] [Related]
18. INI1 expression is retained in composite rhabdoid tumors, including rhabdoid meningiomas.
Perry A; Fuller CE; Judkins AR; Dehner LP; Biegel JA
Mod Pathol; 2005 Jul; 18(7):951-8. PubMed ID: 15761491
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms.
Judkins AR; Mauger J; Ht A; Rorke LB; Biegel JA
Am J Surg Pathol; 2004 May; 28(5):644-50. PubMed ID: 15105654
[TBL] [Abstract][Full Text] [Related]
20. Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop.
Packer RJ; Biegel JA; Blaney S; Finlay J; Geyer JR; Heideman R; Hilden J; Janss AJ; Kun L; Vezina G; Rorke LB; Smith M
J Pediatr Hematol Oncol; 2002; 24(5):337-42. PubMed ID: 12142780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
